Oct 19 (Reuters) - German drugmaker Boehringer Ingelheim won the first U.S. approval for a new stroke-fighting medicine that will compete in an estimated $10 billion market for drugs to replace the 65-year-old blood thinner warfarin.
The Food and Drug Administration cleared Boehringer's drug, Pradaxa, for preventing strokes in patients with a type of irregular heart beat.
The approval gives Boehringer a head start over several other drugmakers, including partners Bayer (BAYGn.DE) and Johnson & Johnson (JNJ.N), and Bristol-Myers Squibb Co (BMY.N) and Pfizer (PFE.N), that are working on competing drugs.
Pradaxa and potential rivals are alternatives to warfarin, a problematic medicine originally developed as rat poison.
Warfarin is the treatment of choice for people at high risk of stroke due to atrial fibrillation, a common form of irregular heart beat. But the drug interacts badly with food and other medicines, carries a high risk of bleeding and requires regular blood tests.
In September, an FDA advisory panel voted 9-0 to recommend approval of Pradaxa, which also carries a risk of serious bleeding.
The warfarin replacement market is expected to be worth more than $10 billion a year and possibly as much as $20 billion.
Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.” Email: jackfriday2011(at)hotmail.co.uk
Wednesday, October 20, 2010
Clot Wars contd. - Boehringer wins first US OK in blood-thinner race | Reuters
via reuters.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment